Your PD-L1 proficiency helps enable precision medicine for patients. Sharpen your command of this landmark biomarker with the cutting-edge webinar series from Agilent.
The series in detail
The Precision Pathology Insights series gives you access to leading perspectives on PD-L1:
The 2019 Program is now available to view on-demand at your convenience.
The Pathologist and the Oncologist: Working Together on PD-L1 to Improve Patient Treatment
Dr. Jose Ramirez, MD
Consultant in Pathology, Hospital Clinic of Barcelona; Professor of Pathology, University of Barcelona, Spain
Dr. Noemí Reguart Aransay, MD, PhD
Consultant Oncologist, Department of Medical Oncology, Hospital Clinic of Barcelona, Spain
External Quality Assurance of PD-L1 Assays: The NordiQC Experience
Dr. Mogens Vyberg, MD
Professor, Aalborg University, Denmark;
Consultant, NordiQC
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA® (pembrolizumab)
Dr. Kristopher Kersch, MD
Pathologist,
Agilent Technologies
The Value of Companion Diagnostic (CDx) Assays in the Complex Environment of PD-L1 Testing
Dr. Allen Gown, BS, MD
Founder and Senior Pathologist, PhenoPath Laboratories;
Clinical Professor,
Dept. of Pathology,
University of British Columbia
The complete Precision Pathology Insights series from Agilent can be accessed here: https://www.agilent.com/en/training-events/eseminars/pathology
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.